Clinical trials: Urinary Complications
Recurrent Calcic Urolithiasis
Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis
The purpose of this study is to determine whether Renalof administration promotes partial or total dissolution of urinary calculi and improves physicochemical parameters and metabolic activity in patients with recurrent calcic…
- Trial name
- NCT01022060
- Testing
- Renalof
- Where
- Cuba
- Volunteers
- 110 people
- Sponsor
- Catalysis SL
Urinary Retention, Neurogenic Bladder
Connected Catheter (C2P) Study for Bladder Management
The objective of this study is to evaluate the safety and essential performance of the C2P System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting and an extended period of home…
- Trial name
- NCT03626324
- Testing
- C2P
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spinal Singularity
Stress Urinary Incontinence (SUI)
A Study of Two Versions of the Uresta Pessary Handle for Women With Stress Urinary Incontinence
The goal of this clinical trial is to learn if a new handle design for the uresta pessary works better than the current handle design for women when they are using the pessary.
- Trial name
- NCT07706491
- Testing
- pessary handle
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Resilia Inc.
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Urinary Incontinence, Overactive Bladder
Tactile Imaging and Electromyography
Urinary incontinence (UI) and overactive bladder (OAB) in women has high prevalence which is increasing with the age. In adults aged 40 and older in the US demonstrated prevalence rate of 27.2% among man and 43.1% among women…
- Trial name
- NCT03477214
- Testing
- Biomechanical and electromyography mapping
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Advanced Tactile Imaging, Inc.
Cystitis
Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)
This study is to assess if the efficacy of cephalosporin is similar to the efficacy of norfloxacin in the acute cystitis treatment.
- Trial name
- CECI (NCT01527019)
- Testing
- Norfloxacin, Cephalosporins
- Sponsor
- Eurofarma Laboratorios S.A.
Urinary Stress Incontinence
Efficacy and Safety of Duloxetine
The purpose of this study is to monitor the long term safety and efficacy of duloxetine in the treatment of severe pure genuine stress incontinence.
- Trial name
- NCT00190619
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder, Neurogenic
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old.
- Trial name
- NCT01557244
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin
- Where
- 84 sites in United States, Belgium and 23 more
- Volunteers
- 181 people
- Sponsor
- Pfizer
Bladder Cancers
Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)
The purpose of the study is the identification of chromosomal aberrations in urine samples. The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of UroVysion…
- Trial name
- NCT01264744
- Where
- 3 sites in United States
- Volunteers
- 174 people
- Sponsor
- Applied Spectral Imaging Ltd.
Urinary Incontinence, Urinary Obstruction
NXT Post-Market Clinical Follow-up
NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations
- Conditions
- Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
- Trial name
- NCT06336304
- Testing
- Urodynamic procedure
- Where
- 5 sites in United States
- Volunteers
- 163 people
- Sponsor
- Laborie Medical Technologies Inc.
Non-muscle-invasive Bladder Cancer
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
- Trial name
- NCT05710848
- Testing
- STM-416
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- SURGE Therapeutics
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Overactive Bladder
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance…
- Trial name
- POTTOR (NCT01488578)
- Testing
- Tolterodine tartrate
- Volunteers
- 11,157 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bladder Cancer, Adult Solid Tumor
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
This is a multi-center, stratified and single-blinded Phase 2 trial of neoadjuvant immunotherapy in combination with the anti-GDF15 antibody visugromab (CTL-002) for the treatment of participants with MIBC set to undergo radical…
- Trial name
- NCT06059547
- Testing
- Nivolumab, Visugromab (CTL-002)
- Where
- 4 sites in Italy
- Volunteers
- 31 people
- Sponsor
- CatalYm GmbH
Interstitial Cystitis
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
This is a pilot clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive either an active product (Uracyst®) or placebo intravesically via a bladder…
- Trial name
- NCT00527917
- Testing
- Uracyst
- Where
- 13 sites in Canada
- Volunteers
- 65 people
- Sponsor
- Watson Pharmaceuticals
Urinary Stress Incontinence
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence
The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
- Trial name
- NCT00190606
- Testing
- Duloxetine, Pelvic Floor Muscle Training (PFMT), Imitation PFMT
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Respiratory Tract Infections, Urinary Tract Infections
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected infections.
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Intraabdominal Infections
- Trial name
- NCT03744741
- Testing
- HostDx Sepsis
- Where
- 7 sites in United States, Greece
- Volunteers
- 585 people
- Sponsor
- Inflammatix
Urinary Bladder, Overactive
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB).
- Trial name
- NCT01314872
- Testing
- Vibegron, Tolterodine ER
- Volunteers
- 1,395 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Transitional Cell, Bladder Cancer
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer.
- Conditions
- Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
- Trial name
- NCT00722553
- Testing
- Pralatrexate Injection, Vitamin B12, Folic Acid
- Where
- 19 sites in United States, Argentina and 4 more
- Volunteers
- 30 people
- Sponsor
- Acrotech Biopharma Inc.
Urinary Bladder Overactive, Overactive Bladder
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
- Trial name
- PERSPECTIVE (NCT02386072)
- Testing
- mirabegron, antimuscarinic medication
- Where
- 92 sites in United States, Canada
- Volunteers
- 1,524 people
- Sponsor
- Astellas Scientific & Medical Affairs, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.